GLP-1 Revolution
GLP-1 drugs will be the biggest-selling class of pharmaceuticals in history. We're watching the birth of a $100 billion market in real time.
Stoquity AI Committee1Strategy Overview
GLP-1 Revolution is Stoquity's most concentrated thematic portfolio, targeting the companies at the forefront of the GLP-1 receptor agonist revolution. These drugs — originally developed for type 2 diabetes — have shown remarkable efficacy in treating obesity, cardiovascular disease, NASH (fatty liver), and potentially Alzheimer's and addiction.
The portfolio is deliberately concentrated in 8 positions because the GLP-1 opportunity is dominated by a small number of companies with approved products, advanced pipelines, and manufacturing capability. The top two holdings (Eli Lilly and Novo Nordisk) represent over 34% of the portfolio — reflecting their dominant position in a winner-take-most market.
GLP-1 drugs are not diet pills — they're metabolic reset buttons. The SELECT cardiovascular outcomes trial showed Wegovy reduced major adverse cardiovascular events by 20%. Clinical trials are now testing GLP-1s for Alzheimer's, alcohol addiction, sleep apnea, and kidney disease. Each new indication expands the addressable market by billions.
2Investment Thesis
Obesity affects over 1 billion adults globally. In the United States, 42% of adults are obese — driving $173B in annual medical costs. Until GLP-1 agonists, no pharmaceutical intervention produced sustained, meaningful weight loss. Semaglutide (Wegovy) achieves 15-17% weight loss; tirzepatide (Zepbound) achieves 20-25%.
The commercial opportunity is staggering. GLP-1 drug sales reached $40B in 2024 and are projected to exceed $100B by 2030. Supply constraints — not demand — are the current bottleneck. Both Eli Lilly and Novo Nordisk are investing billions in manufacturing capacity. When supply catches up with demand, the growth acceleration will be unprecedented in pharmaceutical history.
These drugs are the most significant advance in metabolic medicine in 50 years. The clinical data is unprecedented — and we're still in the early innings of understanding their full therapeutic potential.
Adapted from American Diabetes Association Commentary (2025)3How the Strategy Works
The GLP-1 scoring model evaluates companies across three layers:
1. Core GLP-1 Exposure — direct GLP-1 revenue or late-stage pipeline candidates, manufacturing capabilities, and patent protection 2. Ecosystem Beneficiaries — companies whose products benefit from GLP-1 adoption (glucose monitors, surgical volume increases, diabetes management devices) 3. Next-Generation Candidates — companies developing improved GLP-1 formulations (oral delivery, longer-acting, combination therapies)
The portfolio rebalances weekly to capture rapid clinical catalyst developments while maintaining core positions in the two market leaders.
| Factor | Weight | Rationale |
|---|---|---|
| Revenue Growth | 22% | GLP-1 companies are experiencing the fastest revenue growth in pharma history |
| Momentum | 18% | Strong momentum reflects accelerating commercial adoption and clinical catalysts |
| Quality | 16% | Only high-quality companies can execute on manufacturing and clinical programs simultaneously |
| Earnings Surprise | 14% | GLP-1 companies consistently beat estimates as demand exceeds forecasts |
| Operating Margin | 10% | Improving margins signal manufacturing scale and pricing power |
| Free Cash Flow Yield | 8% | Cash generation funds massive manufacturing expansion capex |
4Risk Metrics
| Metric | Value |
|---|---|
| Sharpe Ratio | 1.48 |
| Beta | 1.24 |
| Alpha | 32.4 |
| Sortino Ratio | 1.72 |
| VaR (95%) | -5.6% |
| Max Drawdown | -18.4% |
| HHI (Concentration) | 0.14 |
| Annual Return | 42.8% |
| Volatility | 26.2% |
5Current Holdings
| Symbol | Company | Weight | Score | Sector |
|---|---|---|---|---|
| LLY | Eli Lilly | 18.2% | 97 | Healthcare |
| NVO | Novo Nordisk | 16.4% | 95 | Healthcare |
| AMGN | Amgen | 8.6% | 88 | Healthcare |
| VKTX | Viking Therapeutics | 7.2% | 86 | Healthcare |
| AZN | AstraZeneca | 6.8% | 84 | Healthcare |
| ISRG | Intuitive Surgical | 5.4% | 89 | Healthcare |
| DXCM | DexCom | 5% | 83 | Healthcare |
| PODD | Insulet Corporation | 4.8% | 82 | Healthcare |
6Recent Trades
| Date | Action | Symbol | Shares | Price |
|---|---|---|---|---|
| 2026-03-12 | ADD | LLY | 6 | $852.4 |
| 2026-03-07 | ADD | NVO | 20 | $128.6 |
| 2026-03-01 | BUY | VKTX | 50 | $78.4 |
7Risk Considerations
GLP-1 Revolution is a concentrated, single-theme portfolio with above-average volatility. The top two holdings represent 34%+ of the portfolio — a deliberate choice but one that amplifies single-stock risk.
Specific risks include: competition from next-generation GLP-1 candidates that could disrupt current market leaders, pricing pressure from insurance companies or government programs, safety signals emerging from long-term use data, and manufacturing bottlenecks delaying revenue recognition.
The portfolio also faces the risk of being "too successful" — if GLP-1 drugs dramatically reduce obesity rates, companies selling to obese patients (medical devices, bariatric surgery) could see demand declines. The Drawdown Governor triggers at -20%.
Two stocks (Eli Lilly and Novo Nordisk) represent over 34% of the portfolio. This reflects the winner-take-most dynamics of the GLP-1 market but creates meaningful single-stock risk. Investors should size their GLP-1 Revolution allocation accordingly — this is a satellite position, not a core holding.
8Who Is This For?
GLP-1 Revolution is designed for investors who want concentrated exposure to the most significant pharmaceutical opportunity in a generation. Requires comfort with healthcare sector volatility and concentrated positions.
| Investor Types | Healthcare thematic investors, Concentrated growth seekers, Pharmaceutical catalyst investors |
| Time Horizon | 3-7 years |
| Risk Profile | Aggressive — concentrated single-theme exposure |
| Income Needs | Low — GLP-1 companies reinvest in R&D and manufacturing |
Follow GLP-1 Revolution
Track the obesity and metabolic disease revolution with real-time GLP-1 portfolio analytics and clinical catalyst monitoring.
Start Free →